



## Keratin-pan (Acetyl Lys185) mouse mAb

10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,		
Reactivity Human;Mouse;Rat  Applications WB  Gene Name KRT2 KRT2A KRT2E  Protein Name Keratin-pan (Acetyl Lys185)  Immunogen Synthesized peptide derived from human Keratin-pan (Acetyl Lys185)  Specificity This antibody detects endogenous levels of Human,Mouse,Rat Keratin-pan (Acetyl Lys185)  Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.  Source Monoclonal, Mouse, IgG  Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.  Dilution WB 1:500-2000  Concentration 1 mg/ml  Purity ≥90%  Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;Kze;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertropic and kelold scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in beingn keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function developmental stage: Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing developmental stage: Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate level of lunk skin. At 19.3 weeks, tegetode of the intermediate level of lunk skin. At 19.3 weeks, tegetode of the intermediate layer of lunk skin. At 19.3 weeks, tegetode of the expression patterns were observed in upper intermediate keratinocytes of cheek,	Catalog No	BYmab-02908
Applications  Gene Name  KRT2 KRT2A KRT2E  Protein Name  Keratin-pan (Acetyl Lys185)  Immunogen  Synthesized peptide derived from human Keratin-pan (Acetyl Lys185)  Specificity  This antibody detects endogenous levels of Human,Mouse,Rat Keratin-pan (Acetyl Lys185)  Formulation  Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.  Source  Monoclonal, Mouse,IgG  Purification  The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.  Dilution  WB 1:500-2000  Concentration  1 mg/ml  Purity  ≥90%  Storage Stability  -20°C/1 year  Synonyms  Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2e;Keratin-2e;Kez;Type-II keratin Kb2)  Observed Band  70kD  Cell Pathway  Tissue Specificity  Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squarmous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benigh keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage: Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.2 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Isotype	IgG
Gene Name         KRT2 KRT2A KRT2E           Protein Name         Keratin-pan (Acetyl Lys185)           Immunogen         Synthesized peptide derived from human Keratin-pan (Acetyl Lys185)           Specificity         This antibody detects endogenous levels of Human, Mouse, Rat Keratin-pan (Acetyl Lys185)           Formulation         Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.           Source         Monoclonal, Mouse, IgG           Purification         The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.           Dilution         WB 1:500-2000           Concentration         1 mg/ml           Purity         ≥90%           Storage Stability         -20°C/1 year           Synonyms         Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;Keratin-Rezin Kb2)           Observed Band         70kD           Cell Pathway         Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benigh keratinozation.           Function         developmental stage:Synthesized during maturation of	Reactivity	Human;Mouse;Rat
Protein Name Keratin-pan (Acetyl Lys185)  Immunogen Synthesized peptide derived from human Keratin-pan (Acetyl Lys185)  Specificity This antibody detects endogenous levels of Human,Mouse,Rat Keratin-pan (Acetyl Lys185)  Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.  Source Monoclonal, Mouse,IgG  Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.  Dilution WB 1:500-2000  Concentration 1 mg/ml  Purity ≥90%  Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast ripple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function developmental stage.Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, detected in scattered ce	Applications	WB
Immunogen         Synthesized peptide derived from human Keratin-pan (Acetyl Lys185)           Specificity         This antibody detects endogenous levels of Human,Mouse,Rat Keratin-pan (Acetyl Lys185)           Formulation         Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.           Source         Monoclonal, Mouse,IgG           Purification         The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.           Dilution         WB 1:500-2000           Concentration         1 mg/ml           Purity         ≥90%           Storage Stability         -20°C/1 year           Synonyms         Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;Kez;Type-II keratin Kb2)           Observed Band         70kD           Cell Pathway           Tissue Specificity         Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.           Function         developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the uppe	Gene Name	KRT2 KRT2A KRT2E
Specificity (This antibody detects endogenous levels of Human,Mouse,Rat Keratin-pan (Acetyl Lys185)  Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.  Source Monoclonal, Mouse,IgG  Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.  Dilution WB 1:500-2000  Concentration 1 mg/ml  Purity ≥90%  Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal ginglua mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek, regional expression patterns were observed in upper intermediate keratinocytes of cheek.	Protein Name	Keratin-pan (Acetyl Lys185)
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.  Source Monoclonal, Mouse, IgG  Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.  Dilution WB 1:500-2000 Concentration 1 mg/ml  Purity ≥90% Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and kelold scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek.	Immunogen	Synthesized peptide derived from human Keratin-pan (Acetyl Lys185)
Source       Monoclonal, Mouse,IgG         Purification       The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.         Dilution       WB 1:500-2000         Concentration       1 mg/ml         Purity       ≥90%         Storage Stability       -20°C/1 year         Synonyms       Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;Keratin-Kb2)         Observed Band       70kD         Cell Pathway         Tissue Specificity       Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and kelold scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.         Function       developmental stage. Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is in 10 weeks in the developing embryo in the presumptive nall bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 19.3 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, geigonal expression patterns were observed in upper intermediate keratinocytes of cheek,	Specificity	This antibody detects endogenous levels of Human, Mouse, Rat Keratin-pan (Acetyl Lys185)
Purification The antibody was affinity-purified from mouse antiserum by affinity-chromatography using epitope-specific immunogen.  Dilution WB 1:500-2000 Concentration 1 mg/ml Purity 290% Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage: Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Formulation	
affinity-chromatography using epitope-specific immunogen.  WB 1:500-2000  Concentration 1 mg/ml  Purity ≥90%  Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Source	Monoclonal, Mouse,IgG
Concentration       1 mg/ml         Purity       ≥90%         Storage Stability       -20°C/1 year         Synonyms       Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)         Observed Band       70kD         Cell Pathway         Tissue Specificity       Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.         Function       developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks, At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Purification	·
Purity ≥90%  Storage Stability -20°C/1 year  Synonyms Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band 70kD  Cell Pathway  Tissue Specificity Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Dilution	WB 1:500-2000
Synonyms  Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2 epidermis;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band  70kD  Cell Pathway  Tissue Specificity  Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Concentration	1 mg/ml
Synonyms  Keratin, type II cytoskeletal 2 epidermal (Cytokeratin-2e;CK-2e;Epithelial keratin-2e;Keratin-2e;Keratin-2e;Keratin-2e;K2e;Type-II keratin Kb2)  Observed Band  70kD  Cell Pathway  Tissue Specificity  Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Purity	≥90%
Cell Pathway  Tissue Specificity  Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  Function  developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Storage Stability	-20°C/1 year
Tissue Specificity  Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Synonyms	
Tissue Specificity  Expressed in the upper spinous and granular suprabasal layers of normal adult epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Observed Band	70kD
epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in mild-to-moderate oral dysplasia with orthokeratinization.  Function  developmental stage:Synthesized during maturation of epidermal keratinocytes and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Cell Pathway	
and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional expression patterns were observed in upper intermediate keratinocytes of cheek,	Tissue Specificity	epidermal tissues from most body sites including thigh, breast nipple, foot sole, penile shaft and axilla. Not present in foreskin, squamous metaplasias and carcinomas. Expression in hypertrophic and keloid scars begins in the deepest suprabasal layer. Weakly expressed in normal gingiva and tongue, however expression is induced in benign keratoses of lingual mucosa and in
	Function	and localized in the upper intermediate cells of fetal skin. Earliest expression is at 10 weeks in the developing embryo in the presumptive nail bed of developing digits, shifting to the proximal nail fold by 13.5 weeks. At 12.5 weeks, detected in scattered cells of the intermediate layer of trunk skin. At 19.3 weeks, regional

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658



国内优质抗体供应商 精准的 WB 检测服务 24H 在线服务,欢迎咨询



	trunk, dorsal and ventral knee, elbow and dorsal hand. Distal areas around the periumbilical region showed increased number of positive cells and by 15 weeks is expressed in small groups of cells in the fetal hair follicles.,disease:Defects in KRT2 are a cause of ichthyosis bullosa of Siemens (IBS) [MIM:146800]. IBS is a rare autosomal dominant skin disorder displaying a type of epidermolytic hyperkeratosis cha
Background	keratin 2(KRT2) Homo sapiens The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is expressed largely in the upper spinous layer of epidermal keratinocytes and mutations in this gene have been associated with bullous congenital ichthyosiform erythroderma. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq, Jul 2008],
matters needing attention	Avoid repeated freezing and thawing!
Usage suggestions	This product can be used in immunological reaction related experiments. For more information, please consult technical personnel.

## **Products Images**

Nanjing BYabscience technology Co.,Ltd

网址: www.njbybio.com 官方热线: 025-5229-8998 监督电话: 15950492658